Compare CAE & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | ROIV |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 14.1B |
| IPO Year | N/A | N/A |
| Metric | CAE | ROIV |
|---|---|---|
| Price | $30.93 | $21.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $33.75 | $24.31 |
| AVG Volume (30 Days) | 572.2K | ★ 8.3M |
| Earning Date | 02-12-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $3,470,482,234.00 | $20,329,000.00 |
| Revenue This Year | $6.40 | N/A |
| Revenue Next Year | $5.37 | $741.42 |
| P/E Ratio | $31.79 | ★ N/A |
| Revenue Growth | ★ 9.12 | N/A |
| 52 Week Low | $20.36 | $8.73 |
| 52 Week High | $31.68 | $23.47 |
| Indicator | CAE | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 56.28 |
| Support Level | $30.38 | $21.36 |
| Resistance Level | $31.68 | $22.72 |
| Average True Range (ATR) | 0.67 | 0.72 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 76.95 | 32.69 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: Civil Aviation which offers comprehensive training solutions for flight, cabin, maintenance, and ground personnel in commercial, business, and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training, and crew sourcing services, as well as aircraft flight operations solutions; and Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.